FY2030 Earnings Forecast for UNCY Issued By HC Wainwright

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Analysts at HC Wainwright issued their FY2030 EPS estimates for Unicycive Therapeutics in a research note issued on Monday, January 26th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of $9.77 for the year. HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share.

UNCY has been the subject of several other research reports. Guggenheim reiterated a “buy” rating on shares of Unicycive Therapeutics in a report on Tuesday, December 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a research note on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, November 2nd. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Unicycive Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $34.33.

Unicycive Therapeutics Trading Up 4.7%

Shares of UNCY opened at $7.20 on Tuesday. Unicycive Therapeutics has a 1-year low of $3.71 and a 1-year high of $11.00. The firm’s 50-day moving average price is $6.08 and its 200-day moving average price is $5.05. The firm has a market capitalization of $154.73 million, a price-to-earnings ratio of -1.82 and a beta of 1.85.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its earnings results on Wednesday, November 12th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.20.

Institutional Trading of Unicycive Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Lazard Asset Management LLC acquired a new position in shares of Unicycive Therapeutics during the 2nd quarter worth approximately $55,000. JPMorgan Chase & Co. grew its holdings in Unicycive Therapeutics by 11,698.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after buying an additional 21,525 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Unicycive Therapeutics in the 3rd quarter worth $182,000. Squarepoint Ops LLC purchased a new position in shares of Unicycive Therapeutics during the 3rd quarter worth $512,000. Finally, Vanguard Group Inc. raised its holdings in shares of Unicycive Therapeutics by 8.7% during the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock worth $2,873,000 after acquiring an additional 52,925 shares during the period. Institutional investors and hedge funds own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.